Although trastuzumab has changed the paradigm for HER2-positive breast cancer treatment and significantly improved patients’ prognosis, about 35% of patients have natural resistance, and about 70% of patients who initially respond to trastuzumab treatment progress to metastatic disease and develop resistance within 1 year [12, 16]. Here, ERBB2 is linked to breast cancer.